8-K: Standard BioTools Reports Strong 2023 Results, Completes SomaLogic Merger

Standard BioTools achieved its 2023 financial objectives, significantly reducing expenses and cash burn while increasing revenue and gross margins, and completed its merger with SomaLogic.

Summary

• Standard BioTools announced its financial results for the fourth quarter and full year of 2023, highlighting significant progress in operational efficiency and strategic growth.
• The company achieved a 9% increase in total revenue for fiscal year 2023 and a 4% increase in the fourth quarter, with instrument sales growing by 46% for the year and 44% in the fourth quarter.
• Non-GAAP gross margin expanded by 900 basis points to 60.1% for the full year and 630 basis points to 59.6% in the fourth quarter.
• Non-GAAP operating expenses decreased by $20 million (17%) for the year and $1 million (5%) in the fourth quarter.
• The company's non-GAAP adjusted EBITDA loss improved by $34 million for the year and over $3 million in the fourth quarter.
• Operating cash use declined by $47 million (53%) for the year and $6 million (32%) in the fourth quarter.
• The merger with SomaLogic was completed on January 5, 2024, and combined pro forma revenue for 2023 was $192 million, with $565 million in combined pro forma cash, cash equivalents, restricted cash, and short-term investments as of December 31, 2023.
• For fiscal year 2024, the combined company expects revenue in the range of $200 million to $205 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strong financial results, successful merger completion, and optimistic outlook. The company's focus on operational efficiency and strategic growth is also encouraging.

Positives

• The company successfully standardized core business units and implemented SBS business systems.
• The team has demonstrated its ability to reduce expenses and cash consumption while returning the business to growth.
• The merger with SomaLogic is expected to create a scaled leader in life sciences tools and services.
• The company is actively seeking new partnerships to scale operations and diversify revenue.
• The company has a strong cash position of $565 million pro forma after the merger.

Negatives

• The company reported a net loss of $74.7 million for the full year 2023.
• The company reported an operating loss of $76.6 million for the full year 2023.
• The company reported a non-GAAP adjusted EBITDA loss of $34.7 million for the full year 2023.

Risks

• The company faces risks related to the integration of the SomaLogic merger.
• There are risks that the anticipated benefits of the merger may not be fully realized or may take longer than expected.
• The company may not realize expected cost savings from restructuring.
• There are risks of disruption from restructuring and transition, including loss of customers, suppliers, and employees.
• The company faces risks related to developing, manufacturing, launching, marketing, and selling new products.
• The company is subject to risks related to supply chain interruptions and delays.
• The company is subject to risks related to competition and intellectual property.
• The company is subject to risks related to changes in customer spending and budget priorities.

Future Outlook

The combined company expects revenue in the range of $200 million to $205 million for fiscal year 2024.

Management Comments

• Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, stated that the team hit its major target of standardizing the core business units and instilling SBS business systems throughout the organization.
• Egholm also noted that the team is executing with a laser-focus on operational discipline, behind a clear strategy to bring together unique technologies under one roof.
• Egholm expressed confidence that the team is well positioned to achieve scale and profitability.
• Egholm stated that the merger integration process is well underway and the company is building significant momentum.
• Egholm believes the best is yet to come for Standard BioTools and SomaLogic, stating 'we are better together'.

Industry Context

This announcement reflects a trend in the life sciences industry towards consolidation and the pursuit of operational efficiencies. The merger with SomaLogic positions Standard BioTools to compete more effectively by offering a broader range of technologies and services.

Comparison to Industry Standards

• The 9% revenue growth for the year is a solid result in the life sciences tools sector, although some high-growth companies may be experiencing higher growth rates.
• The expansion of non-GAAP gross margin to 60.1% is a positive sign, indicating improved profitability and cost management, which is comparable to other established life science companies such as Agilent and Thermo Fisher.
• The reduction in operating expenses by 17% is a significant achievement, demonstrating the company's focus on efficiency, which is a key metric for investors in this sector.
• The pro forma cash position of $565 million is strong and provides a solid foundation for future growth and strategic initiatives, which is comparable to other companies with recent mergers such as Illumina and GRAIL.
• The revenue guidance of $200-$205 million for 2024 is a modest increase, suggesting a focus on integration and operational improvements rather than aggressive growth, which is a common approach for companies post-merger.

Stakeholder Impact

• Shareholders should be encouraged by the improved financial performance and strategic direction.
• Employees may experience changes due to the merger integration process.
• Customers should benefit from the expanded range of technologies and services.
• Suppliers may see changes in their relationships with the company due to the merger.

Next Steps

• The company will continue to integrate the SomaLogic business.
• The company will focus on scaling operations and diversifying revenue.
• The company will continue to identify new partners with emerging technologies and businesses.

Key Dates

Keywords

Standard BioTools, SomaLogic, Merger, Financial Results, Revenue, Gross Margin, Operating Expenses, EBITDA, Cash Flow, Life Sciences, Biotechnology, Mass Cytometry, Microfluidics